The Midwest CEPAC convened in September 2018 to review ICER's report on treatments for hereditary transthyretin-related (hATTR) amyloidosis, a rare genetic condition characterized by nerve, heart, and eye damage that is currently treated through supportive measures alone. See the Policy Roundtable discussion here.
Ещё видео!